.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Johnson and Johnson
Federal Trade Commission
Medtronic
Express Scripts
Novartis
Chubb
Cerilliant
Merck

Generated: November 22, 2017

DrugPatentWatch Database Preview

VESPRIN Drug Profile

« Back to Dashboard

Which patents cover Vesprin, and when can generic versions of Vesprin launch?

Vesprin is a drug marketed by Bristol Myers Squibb and Apothecon and is included in three NDAs.

The generic ingredient in VESPRIN is triflupromazine. There are two drug master file entries for this compound. Additional details are available on the triflupromazine profile page.

Medical Subject Heading (MeSH) Categories for VESPRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
VESPRIN
triflupromazine hydrochloride
TABLET;ORAL011123-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Apothecon
VESPRIN
triflupromazine
SUSPENSION;ORAL011491-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Apothecon
VESPRIN
triflupromazine hydrochloride
INJECTABLE;INJECTION011325-005Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
VESPRIN
triflupromazine hydrochloride
TABLET;ORAL011123-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
VESPRIN
triflupromazine hydrochloride
TABLET;ORAL011123-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Apothecon
VESPRIN
triflupromazine hydrochloride
INJECTABLE;INJECTION011325-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Apothecon
VESPRIN
triflupromazine hydrochloride
INJECTABLE;INJECTION011325-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
Medtronic
QuintilesIMS
Fuji
Julphar
Cantor Fitzgerald
Boehringer Ingelheim
Harvard Business School
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot